Value of measuring serum FSH in addition to serum estradiol in a coasting programme to prevent severe OHSS

Human Reproduction

Volumn 17, Issue 5, 2002, Pages 1217-1221

  Al Shawaf, T ^a   Zosmer, A ^a   Tozer, A ^a   Gillott, C ^a   Lower, A M ^a   Grudzinskas, J G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Assisted reproduction; Coasting; OHSS; Serum estradiol; Serum FSH

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FETUS OUTCOME; FOLLITROPIN BLOOD LEVEL; HIGH RISK PATIENT; HORMONE DETERMINATION; HUMAN; INFERTILITY; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREDICTION; PREGNANCY; PROSPECTIVE STUDY; SAFETY; SENSITIVITY AND SPECIFICITY;

FALLOPIA;

EID: 0036099622     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.5.1217     Document Type: Article

References (27)

1. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: A modified 'coasting' strategy based on ultrasound for identification of high-risk patients
2. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups
3. Ovarian response of individuals to different doses of human menopausal gonadotropin
4. Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation
5. The significance of 17β-estradiol levels in highly responding women during ovulation induction in IVF treatment: Its impact and prognostic value with respect to oocyte maturation and treatment outcome
6. Differences in ovarian stimulation in human menopausal gonadotropin treated women may be related to follicle-stimulating hormone accumulation
7. Pharmacokinetics of follicle stimulating hormone: Clinical significance
8. Ovarian hyperstimulation syndrome: Prediction by number and size of preovulatory ovarian follicles
9. Pituitary control of ovarian function - Concepts derived from gonadotrophin therapy
10. Influence of ovulation with human menopausal gonadotropin and human chorionic gonadotropin
11. Clinical-pharmacological studies on human menopausal gonadotrophin
12. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: A prospective randomized study
13. Ethical issues on studies on the prevention of severe ovarian hyperstimulation syndrome
14. Serum estradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment
15. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilisation
16. Withholding gonadotrophin ('coasting') to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo treatment cycles
17. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single dose and steady state pharmacokinetics
18. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
19. Circulating bioactive and immunoreactive recombinant human follicle-stimulating hormone (Org32489) after administration to gonadotropin deficient subjects
20. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment
21. Clinical pharmacology of recombinant follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated administration
22. 'Prolonged coasting': An effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization
23. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism
24. Gonadotropins for induction of ovulation, immunological, pharmacological and clinical studies
25. Pharmacodynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease
26. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: A multicentre study
27. Disappearance rates of endogenous follicle-stimulating hormone in serum following hypophysectomy in man